How Much Mitragynine Are You Actually Taking? The Number Behind Tolerance

Every certificate of analysis in this category contains a figure that answers the question underneath dependence, and almost nobody reads it. This page is about that figure. It is also, unavoidably, about us, because King K sells the concentrated end of this category and the concentrated end is where the figure is largest.

The sentence a health department wrote that should have been the headline

When Massachusetts prepared for its prohibition, its health department did not lead with enforcement. It led with a warning about bodies. Its guidance page says that these products "can act like potent opioids" and that "people who regularly use these products are likely to experience opioid tolerance and withdrawal symptoms when they stop or reduce their use, including craving, nausea, diarrhea, muscle and head aches, sniffling, sneezing, sweating, and irritability." You can read the whole page at mass.gov.

The same page is blunter still a few paragraphs down: "Physical dependence develops when an individual takes kratom products often and consistently. This results in unpleasant withdrawal symptoms when they stop taking it. Many people take kratom products and do not realize that it could be harmful or that dependence can occur."

Read the two words at the heart of that first quotation again. Tolerance. Withdrawal. They are not decorative. They are two of the eleven criteria in the DSM-5 definition of a substance use disorder, and in the survey that produced the prevalence figure everyone quotes, they are the two that were met most often, by a wide margin.

Tolerance and withdrawal are also the two criteria most tightly coupled to a single variable that a manufacturer sets and a laboratory measures. How much of the active alkaloid is in the thing you swallowed.

Potency is the one variable in this whole argument that a seller controls

Almost everything else in the dependence literature is out of a company's hands. We do not set how often you take something, or what else you take with it, or what your liver does with it, or whether you were tapering off something harder when you found us. We set exactly one thing: the concentration of the material we put in the bottle and the tablet. We then hire a laboratory to measure it and we print the result.

That is why this article is on this domain rather than somewhere more comfortable. King K sells liquid extracts and pressed tablets. Within the kratom category, concentrates are the high dose end, and the high dose end is the end where tolerance builds fastest and stopping is hardest. Writing a dependence article on an extract company's blog and pretending the catalogue on the other side of the header is neutral would be worthless.

We have one piece of standing here and it is worth stating precisely. We published a certificate for one of our own tablet lots in which a limit test came back marked FAIL against our own internal specification, and we wrote an article about that failing lot rather than quietly swapping the file. That does not make us a good company. It makes this one sentence checkable, which is the only reason we are entitled to write the rest of the page. That article is about whether a document is real: which lab, which lot, which method, which specification, and what a company does when a result comes back badly. It is the prerequisite for this one.

This one asks the next question. Assume the document is real. What does the number on it mean for a person who takes the product every day for a year?

What the number on our own certificate actually says

Take lot 02122026, the same lot from the failure article, because using our own numbers costs us something and using a competitor's would cost us nothing. The alkaloid panel on that report gives mitragynine at 26.0 percent by weight, which the laboratory converts to 186 mg per tablet using a measured unit weight of 0.713 grams. Total alkaloids across the panel come to 27.2 percent. Loss on drying is 6.09 percent. The report sits with every other certificate we hold on our lab results page.

186 mg per tablet is a large figure. It is not a boast and we would ask you not to read it as one. It is the size of a dose, and the size of a dose is the input to every single thing this article is about. A number that large on a certificate is not evidence that a product is good. It is evidence that a product is strong, which is a different word with different consequences.

Three things about the units, because this is where readers get lost and where sellers are content to leave them. A percentage by weight is a concentration and tells you nothing on its own about how much you took. Milligrams per unit is a dose and is the figure you want. If a certificate gives you only the percentage, the arithmetic is percentage multiplied by the unit weight, and if the unit weight is missing from the report then the report cannot answer the dose question at all.

The multiplication nobody does

Here is the entire method, and it takes about fifteen seconds once you have the certificate open.

Find the milligrams per unit. Multiply by the number of units you take in a day. That product is your daily exposure, and it is the only figure in this whole subject that has a direct mechanical relationship to tolerance. On lot 02122026, one tablet is 186 mg. Two a day is 372 mg. Four a day is 744 mg. We are not going to tell you which of those numbers is yours, and we are not going to tell you what any of them should be, because that is a clinical question and we are not clinicians. What we will say is that most people who take this category daily could not produce that figure if asked, and that it is knowable, from a document that is already published, in less time than it takes to read this paragraph.

Then do it again in three months. A daily exposure figure that climbs while the effect stays flat is the working definition of tolerance, and it is the earliest thing you can observe about your own use without a laboratory, a clinician or anyone's permission. It is also, in our experience of this industry, the number that people most want not to have written down.

What a certificate cannot tell you, and it is more than you would think

A certificate of analysis is a laboratory's report on one sample. One sample, received on a stated date, tested by named methods, against a stated specification. Everything it proves is bounded by those four things, and the boundary is tighter than the marketing around it implies.

It is a lot level snapshot from one laboratory on one date. It says nothing about the lot before it or the lot after it, because botanical inputs vary by harvest and by supplier and by process. It cannot connect itself to the container in your hand except through the lot number, so a package with no lot printed on it has no certificate, whatever the website shows.

And here is the part that matters most on a page about dependence. A certificate cannot tell you what a serving will do to you, and it cannot predict whether you will become dependent. It measures a substance, not a person. There is no threshold published anywhere above which dependence reliably begins and below which it reliably does not, because no such threshold has been established. The main systematic review of kratom withdrawal, in the Journal of Psychoactive Drugs in 2019 at PMID 30614408, is built substantially on case reports, and there is still no agreed severity scale, no agreed timeline and no standardized protocol underneath it.

So the honest version of the claim this page makes is narrow. Reading the number tells you what you are taking. It does not tell you what will happen to you. Those are different sentences and a seller who blurs them is selling you a false sense of control along with the product.

Two states, in their own words, on what stopping is like

Connecticut's Department of Mental Health and Addiction Services is the clearer of the two on the practical question. Its kratom page says that people who have used regularly "may experience significant withdrawal symptoms including muscle aches, insomnia, irritability, anxiety, nausea, and intense cravings", that "medical supervision during withdrawal is strongly recommended", and then, flatly and without qualification, "Do not stop abruptly without consulting a healthcare provider."

That last instruction matters more than anything else on this page, and we would rather you took it from Connecticut than from us. It also cuts against a reflex that a page like this one can accidentally encourage. Learning that your daily exposure is higher than you assumed is not a reason to stop abruptly and unsupervised. It is a reason to have a conversation with somebody qualified to plan a reduction.

Massachusetts adds one operational instruction worth carrying: for someone who has overdosed and has reduced or stopped breathing, its guidance is that "naloxone should be administered as though it were an opioid-related overdose."

The 25.5 percent figure, and the denominator it does not travel with

One number gets quoted constantly in coverage of this subject and it is almost always quoted wrong. In a study published in the Journal of Addiction Medicine in 2024, Hill, Grundmann and Smith surveyed 2,061 current kratom consumers and found that 25.5 percent met criteria for kratom use disorder adapted from the DSM-5, most often through tolerance at 81.3 percent and withdrawal at 68.0 percent. The paper is indexed at PubMed 38441236.

Now the caveat, which has to travel with the figure every single time it is used. That was an anonymous online convenience sample of people who were currently consuming kratom. It is not a population prevalence estimate, it says nothing about people who tried the category and stopped, and the people most likely to answer a long online survey about their kratom use are not a random draw from everyone who uses it. It is emphatically not a population statement about kratom users in general, and any brand or newsroom that rounds it into one has misread the paper.

What the study does support is the specific point this page turns on: within that sample, of the eleven diagnostic criteria available, the two met most often were tolerance and withdrawal. Those are the two that dose drives.

What the treatment evidence actually supports, stated conservatively

Massachusetts writes that "medications used to treat opioid use disorder, like buprenorphine, have been found to be effective for treating kratom use disorder." That sentence is doing a lot of work, and it is worth knowing exactly what sits under it, because a reader deciding what to ask a doctor deserves the real weight of the evidence rather than the confident summary.

What sits under it is Broyan and colleagues, 2022, a case series of 28 patients. That is the citation the state's page points to. A 28 patient case series is real evidence and it is not nothing, but it is not a controlled trial, and describing it as one would be the kind of overstatement this page exists to argue against.

Researchers at the National Institute on Drug Abuse intramural research program put the position more carefully. Writing in Current Psychiatry Reports in 2024, Smith, Epstein and Weiss record that most clinicians select buprenorphine "although there are no controlled studies showing that buprenorphine is safe or efficacious in this patient population." Their paper is at Springer. NIDA's own kratom research page is blunter again: there are currently no approved medical therapies for these conditions.

So the defensible version is this. Clinicians reach for buprenorphine, Massachusetts says it has been found effective, the evidence for that specifically in kratom is a 28 patient case series plus scattered case reports, there are no controlled trials in this population, and the drug's strong evidence base is in opioid use disorder rather than here. Its use for kratom is an extrapolation that clinicians are making in the absence of trials. Emerging, not established.

And the sentence from the top of the page, repeated once because it is the one a seller has the most incentive to leave out: kratom is not a treatment for opioid use disorder and it is not a treatment for withdrawal from opioids or from kratom. If anyone in this industry has implied otherwise to you, including us, we were wrong.

A second number that lost its caveat in transit

The pattern is not confined to the prevalence figure, and the other example is instructive because it points the other way. In JAMA Network Open on 2 March 2026, researchers reported kratom mentions in hospitalizations across the Mass General Brigham system from 2017 to 2024, finding an increase of 14.9 percent a year, with a 95 percent confidence interval of 8.3 to 22.0. That is the figure that travelled.

What did not travel is where the increase sat. The study puts it in the 2017 to 2020 window, at 45.4 percent. The change from 2020 to 2024 was 10.2 percent and was not statistically significant. Emergency department mentions did not rise significantly at all across the period.

We are not citing that to argue the trend is fake, and we would be uncomfortable if you read it that way, because a rising signal in hospital records for a product we sell is not something a company in our position gets to wave away. We are citing it because the discipline is the same discipline as reading a certificate. A number without its interval, its period and its denominator is a claim wearing a number's clothes, and that is true when the number flatters us and when it does not.

What we are not going to tell you to do

There is a version of this article that ends by recommending a purchase. We are not writing it, and if you find a paragraph above that reads as though we did, tell us and we will rewrite it. A page about dependence that resolves into a product recommendation is worse than no page, because it takes the one moment a reader is thinking clearly about their own use and sells into it.

Four things instead, none of which require you to buy anything from anyone.

Find your daily exposure figure. Milligrams per unit from the certificate, multiplied by units per day. Write it somewhere you will find it again in three months.

Check that the lot on your package appears on the certificate you are reading. If it does not, you are reading a document about someone else's material, and the number you just calculated is fiction.

If the number is not published, you cannot do the arithmetic. Ours is on the lab results page. Our own FAQ page is the example, and you should know what is on it before you click. It says "Kratom is generally safe for healthy adults". It gives servings as one cap, half a cap and half a bottle, which is the exact unit this page has just spent two thousand words arguing cannot answer the dose question. It calls one of our formulas "one of the most potent Kratom shots available". It carries no helpline anywhere on it. That first sentence is the one that collides hardest with everything above, because a state health department has written that people who regularly use these products are likely to develop opioid tolerance and withdrawal, and that page needs rewriting. We are pointing at it rather than quietly fixing it first, because a company arguing that you should read the number does not get to hide the page where it stopped printing one. Ask whoever supplies you for a certificate carrying a lot number and a milligrams per unit figure, and ask us for ours the same way. To be explicit, because this is exactly the point where an article like this usually turns into an advertisement: that is not a reason to change where you buy. It is a reason to know what is in the thing you already have.

Take the exposure figure to a clinician, not to a forum and not to us. Especially if the figure has been climbing, and especially before you stop. Connecticut's instruction not to stop abruptly without consulting a healthcare provider applies whatever a certificate says.

That is the whole argument. A certificate of analysis is a document about a substance and you are not a substance, so the number on it is a starting point for a conversation rather than the end of one. But it is a real starting point, it is free, it is already published, and the reason so few people in this category have ever looked at it is that the industry that prints it has not made a habit of asking them to.

Read the number. Then go and find out what it means for you from somebody who does not sell it to you.

This article is general information about laboratory reporting and published research. It is not medical advice, legal advice or a purchase recommendation, and nothing here is a statement that any King K product is safe for any individual or compliant with any current or future rule. Do not start, change or stop use of any product on the basis of a web page. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Not for sale to persons under 21.